Veracyte Inc

Veracyte Inc

  • Price (USD)50.79
  • Today's Change-1.79 / -3.40%
  • Shares traded605.33k
  • 1 Year change+68.35%
  • Beta0.7219
Data delayed at least 15 minutes, as of Jan 15 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

  • Revenue in USD (TTM)112.68m
  • Net income in USD-34.32m
  • Incorporated2006
  • Employees354.00
  • Location
    Veracyte Inc6000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-7606United StatesUSA
  • Phone+1 (650) 243-6300
  • Fax+1 (650) 243-6301
  • Websitehttps://www.veracyte.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
U.S. Physical Therapy, Inc.427.62m30.12m1.66bn5.40k54.986.2629.283.882.352.3533.3720.620.7498--8.0079,188.348.049.4913.0713.9022.5022.8710.738.95--49.020.029948.836.189.5888.3010.3214.5518.89
Pennant Group Inc372.48m7.93m1.77bn4.70k245.9719.76143.604.750.25530.255312.673.180.8836--11.2779,250.641.88--2.28--24.77--2.13----14.040.0077--18.34---83.77------
Genetron Holdings Ltd - ADR60.84m-484.04m1.83bn663.00--2.14--30.00-16.38-16.382.039.630.30988.344.17---246.46---315.23--56.40---795.62--5.68-0.09160.0587--43.63---45.39------
CorVel Corporation560.75m41.27m1.91bn3.82k47.199.4233.053.402.262.2630.6711.301.29--7.76146,638.309.5013.5214.0821.1120.8720.497.366.65----0.00---0.5903.752.6810.637.19--
Addus Homecare Corporation758.82m34.67m1.92bn5.00k55.803.7841.072.532.182.1847.6432.121.15--5.91151,703.505.285.366.066.6129.3027.034.573.32--20.610.1083--25.5815.7058.2816.63-2.61--
MEDNAX Inc2.22bn18.92m1.98bn5.17k99.722.4633.500.89040.2319-8.6526.699.410.5762--5.84430,338.000.49030.29040.56250.3204----0.8510.4587--2.540.6843--1.707.57-544.72--12.04--
Magellan Health Inc5.20bn49.33m2.45bn10.10k48.061.5314.350.47111.975.32206.5561.671.59116.436.41514,379.001.512.202.223.313.623.810.94950.96432.053.100.28890.00-2.1213.75128.02-6.78-0.6287--
BioTelemetry Inc438.83m17.68m2.47bn1.70k148.916.2237.915.630.48320.483212.0011.570.62128.156.79258,134.702.506.712.757.5361.7461.714.038.172.727.320.28540.009.9221.39-30.30--19.16--
Accolade Inc155.57m-48.07m2.55bn1.24k--6.56--16.37-1.13-1.133.487.040.5801--18.14124,453.60-17.92---24.65--43.43---30.90-----9.560.00--39.76--9.08------
Burning Rock Biotech Ltd(ADR)59.81m-69.53m2.60bn753.00--6.51--43.45-0.6832-0.68320.58773.850.2091.883.8584,841.89-18.69---21.06--69.73---89.40--9.59--0.0177--82.74---43.82------
Agape ATP Corp3.13m29.66k2.82bn--107,142.90490.165,230.44902.170.000070.000070.00830.01530.5385--6.91--0.5103--0.5644--73.43--0.9477--5.47--0.00--------------
Veracyte Inc112.68m-34.32m2.89bn354.00--6.83--25.67-0.6819-0.68192.217.310.31547.305.46318,296.60-9.61-24.13-10.04-27.6064.1663.71-30.46-33.0126.28-138.730.0018--30.8225.8145.22--6.37--
Option Care Health Inc2.95bn-41.73m3.18bn5.08k--3.2085.321.08-0.2371-0.237116.525.321.1217.188.97580,333.80-1.59-11.52-1.86-14.1222.8626.89-1.42-
Progyny Inc309.68m3.20m3.90bn167.002,247.6330.61752.8012.590.020.023.381.472.26--5.051,854,365.002.33--4.48--19.75--1.03------0.00--117.92--24.29------
Select Medical Holdings Corporation5.45bn206.43m3.94bn35.70k18.383.797.990.72331.591.5941.987.710.7352--6.64152,543.503.863.095.314.1014.8114.295.253.45--3.420.6592.137.3312.227.634.1110.53--
CareDx Inc169.37m-19.98m4.09bn306.00--15.19--24.15-0.4527-0.45273.785.470.67977.206.80553,500.00-8.02-23.24-9.86-33.2966.3859.09-11.79-32.823.98-121.980.00--65.9536.0153.02--35.51--
Data as of Jan 15 2021. Currency figures normalised to Veracyte Inc's reporting currency: US Dollar USD

Institutional shareholders

67.86%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 30 Sep 20207.02m12.12%
William Blair Investment Management LLCas of 30 Sep 20205.73m9.89%
BlackRock Fund Advisorsas of 30 Sep 20204.20m7.25%
Wellington Management Co. LLPas of 30 Sep 20204.19m7.24%
Invesco Advisers, Inc.as of 30 Sep 20203.58m6.18%
Artisan Partners LPas of 30 Sep 20203.44m5.95%
Gilder, Gagnon, Howe & Co. LLCas of 30 Sep 20203.08m5.32%
Nikko Asset Management Americas, Inc.as of 30 Sep 20202.99m5.17%
The Vanguard Group, Inc.as of 30 Sep 20202.88m4.98%
SSgA Funds Management, Inc.as of 30 Sep 20202.18m3.77%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.